OneSource Specialty Pharma appoints Jeffrey Wong as CBO

OneSource Specialty Pharma Limited has announced the appointment of Jeffrey Wong as the Chief Business Officer (CBO) of the company effective from July 7, 2025.

Wong is a distinguished global commercial executive with over 30 years of experience driving innovation and growth across the biopharmaceutical industry. His career spans leadership in bioprocess products and CDMO services, supporting mammalian, microbial, and cell and gene therapy platforms.

Wong began his journey contributing to the Human Genome Project, where he helped pioneer next-generation DNA and protein sequencing technologies— cornerstones of today’s biologic therapeutics. He later transitioned into biologics manufacturing, playing pivotal roles in regulatory filings and leading FDA approvals for therapies including Viadur and Zenapax.

His most recent role was as Head of Biologics at Syngene International. Over the course of his career, Jeff has held senior leadership positions at Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations. He has spearheaded global strategic partnerships, negotiated multi-year commercial agreements, and consistently delivered commercial growth through strategic deal-making and alliance development.